Summary of Sionna Therapeutics FY Conference Call Company Overview - **Company**: Sionna Therapeutics (NasdaqGM:SION) - **Focus**: Development of NBD1 mechanistic medicines for Cystic Fibrosis (CF) [1][2] Industry Context - **Cystic Fibrosis (CF)**: Despite advancements in CF treatments, a significant unmet need remains, with two-thirds of patients not achieving normal CFTR function [2][7] - **Current Treatments**: Existing therapies like Trikafta and Alyftrek partially correct CFTR function but do not stabilize NBD1, leaving room for improvement [10][11] Core Points and Arguments - **NBD1 Stabilizers**: Sionna aims to revolutionize CF treatment by focusing on NBD1 stabilizers, which could unlock additional CFTR function improvements [2][8] - **F508del Mutation**: The most common mutation causing CF, F508del, leads to instability in the NBD1 region, impairing protein functionality [8][10] - **Preclinical Data**: Sionna's preclinical data suggests that stabilizing NBD1 can significantly improve the protein's ability to function and traffic to the cell surface, showing nearly equivalent efficacy to the triple combination therapy of Trikafta [11][12] - **Dual Combination Therapy**: The company prioritizes developing a dual combination therapy that includes NBD1 as a foundational component, aiming for full normalization of CFTR function [12][146] Clinical Trials and Data - **Phase 2 PreciSION CF Study**: This study will evaluate SION-719 as an add-on to Trikafta, focusing on sweat chloride levels as a primary endpoint [32][33] - **Success Threshold**: The study is powered to detect a change of at least 10 millimoles per liter in sweat chloride, which historically correlates with clinically meaningful improvements in lung function (FEV1) [40][66] - **Sample Size**: The study will involve 16 patients in a two-way crossover design to minimize variability [74][75] Safety and Efficacy Considerations - **Safety Monitoring**: The company emphasizes a strong focus on safety parameters, including liver function tests, while balancing efficacy [172][176] - **Patient Tolerance**: A significant percentage of CF patients (20%) are intolerant to current modulators due to liver enzyme elevations, highlighting the need for new options [170][182] Competitive Landscape - **Vertex Pharmaceuticals**: Vertex previously attempted to target NBD1 but faced challenges due to the shallow binding pockets, leading to the perception of NBD1 as "undruggable" [28][30] - **AbbVie Case Study**: AbbVie's failure to develop a competitive triple combination therapy after Trikafta's launch is attributed to compound failure rather than assay failure [125][126] Future Directions - **Commercial Opportunities**: Sionna sees potential for both dual combination therapies and add-on treatments to existing therapies, aiming to provide more options for patients [146][147] - **Regulatory Engagement**: The company has had straightforward interactions with regulators and collaborates with the Cystic Fibrosis Foundation for trial design and guidance [195][196] Conclusion Sionna Therapeutics is positioned to address significant unmet needs in CF treatment through innovative NBD1 stabilizers, with ongoing clinical trials and a focus on both safety and efficacy. The company aims to provide new therapeutic options that could enhance patient outcomes in a competitive landscape dominated by existing therapies.

Financial Data and Key Metrics Changes - The company raised $219 million in its IPO in February, providing financial flexibility to execute its strategy through 2028 [7] - The company entered Q3 with $325 million in cash, ensuring a cash runway into 2028 [47] Business Line Data and Key Metrics Changes - The company is focused on cystic fibrosis (CF) and is developing two NBD1 stabilizers: SION-719 for an add-on approach and SION-451 for a dual combination strategy [5][6] - The goal is to improve CFTR function in patients, with a target of achieving at least a 10 millimole per liter change in sweat chloride as a primary endpoint in clinical studies [30][69] Market Data and Key Metrics Changes - The CF market is currently valued at $12 billion and is expected to grow to $15 billion [12] - The company aims to create more treatment options for the approximately 85%-90% of CF patients with the F508del mutation, as two-thirds of patients on standard care do not achieve normal CFTR function [16][19] Company Strategy and Development Direction - The company is pursuing a differentiated approach to CF treatment by targeting the NBD1 protein, which has been considered undruggable [4][10] - The strategy includes a dual combination approach to potentially provide meaningful clinical benefits above the current standard of care, which is a triple combination therapy [6][12] - The company is open to exploring new therapeutic areas in the future but is currently focused solely on CF [50][51] Management's Comments on Operating Environment and Future Outlook - Management believes that the current modulators have not fully addressed the unmet needs in CF, as many patients still do not achieve normal CFTR function [16] - The company is confident in its ability to leverage its historical research and partnerships, particularly with the Cystic Fibrosis Foundation, to advance its clinical studies [65][66] - Management emphasized the importance of patient access in pricing strategies, aiming to ensure that new therapies are accessible to patients [60] Other Important Information - The company has licensed three compounds from AbbVie, enhancing its portfolio with clinical data and complementary mechanisms [42][44] - The company is conducting a healthy volunteer phase 1 study for its dual combination strategy, which is expected to inform future development [38][40] Q&A Session Summary Question: What is the company's approach to addressing unmet needs in CF? - The company aims to improve CFTR function and believes that NBD1 stabilization is key to moving more patients to normal CFTR function [16][19] Question: How does the company plan to differentiate its products in the market? - The company is focused on improving efficacy through its dual combination strategy and leveraging historical data to predict clinical outcomes [67][70] Question: What is the expected timeline for clinical data? - The company anticipates data from its phase 2a proof of concept study in mid-2026, which will be crucial for future development decisions [5][30]

Financial Data and Key Metrics Changes - The company raised $219 million in its IPO in February 2025, providing financial flexibility to execute its strategy through 2028 [7] - As of Q3, the company reported having $325 million in cash, ensuring a cash runway into 2028 [46] Business Line Data and Key Metrics Changes - The company is focused on developing two NBD1 stabilizers: SION-719 for an add-on approach to the standard of care and SION-451 for a dual combination strategy [5][6] - The company aims to demonstrate a clinically meaningful improvement of at least 10 millimoles per liter in sweat chloride, which is expected to correlate with a 3-point improvement in FEV1 [34][35] Market Data and Key Metrics Changes - The cystic fibrosis market is currently valued at $12 billion and is projected to grow to $15 billion [12] - The company targets the same patient population as the standard of care, focusing on the F508del mutation, which affects 85%-90% of cystic fibrosis patients [19] Company Strategy and Development Direction - The company aims to transform the standard of care in cystic fibrosis by focusing on the NBD1 target, which has been historically considered undruggable [4][10] - The dual combination strategy is prioritized, with the goal of raising the efficacy bar through innovative combinations of therapies [6][12] Management's Comments on Operating Environment and Future Outlook - Management believes that there is a significant unmet need in the cystic fibrosis community, as two-thirds of patients on standard care do not achieve normal CFTR function [16] - The company is optimistic about its clinical development strategy and the potential to improve patient outcomes significantly [70] Other Important Information - The company has licensed three compounds from AbbVie, enhancing its portfolio with clinical data and complementary mechanisms [41][42] - The Therapeutics Development Network (TDN) of the Cystic Fibrosis Foundation is a key partner, providing access to a well-organized research network [65][66] Q&A Session Summary Question: What is the company's strategy for addressing the unmet needs in cystic fibrosis? - The company aims to improve CFTR function in patients who are currently on standard care but do not achieve normal function, focusing on the NBD1 stabilization approach [16][19] Question: How does the company plan to differentiate its products in the market? - The company plans to leverage its unique dual combination strategy and the historical data from its assays to demonstrate improved efficacy compared to existing therapies [6][70] Question: What are the expected timelines for clinical data? - The company anticipates data from its phase 2a proof of concept study in mid-2026, which will be crucial for informing future development and capital raising decisions [5][29]

Summary of Ciona Therapeutics Conference Call Company Overview - **Company**: Ciona Therapeutics - **Focus**: Development of novel therapies for cystic fibrosis (CF) targeting CFTR function Key Industry Insights - **Cystic Fibrosis Market**: - Current market size exceeds $11 billion and is expected to grow - Approximately two-thirds of CF patients do not achieve normal CFTR function despite existing treatments [6][34] - The most common mutation, F508L, affects about 90% of CF patients [9] Core Points and Arguments - **Phase I Data**: - Positive results for compounds CYON-seven 19 and CYON-four 51, indicating potential for significant clinical benefits [4][11] - Both compounds exceeded pharmacokinetic targets and demonstrated favorable tolerability profiles [11][20] - **Targeting NDD1**: - NDD1 is identified as a key target for normalizing CFTR function, which has been historically considered undruggable [6][7] - Ciona aims to provide a unique and clinically meaningful option for CF patients by stabilizing NDD1 [5][10] - **Clinical Strategy**: - Plans to advance CYON-seven 19 into a Phase 2a trial as an add-on to standard care (Trikafta) [12][28] - CYON-four 51 will be evaluated in a dual combination trial with complementary modulators [12][32] - Both trials are expected to initiate in the second half of 2025, with data anticipated by mid-2026 [14][28] - **Clinical Assays**: - The CF human bronchial epithelial (CFHBE) assay is critical for predicting clinical outcomes and guiding development [21][22] - Data from the CFHBE assay indicates that both compounds are positioned to deliver meaningful clinical benefits [23][27] Additional Important Information - **Safety and Tolerability**: - No serious adverse events reported in Phase I trials for both compounds, supporting their advancement to further studies [20][26] - Mild to moderate treatment-emergent adverse events were observed, with no dose-limiting toxicities [20][26] - **Market Opportunity**: - Ciona is focused on the unmet needs of CF patients, particularly those with the F508del mutation, and aims to improve CFTR function significantly [34][36] - The company is well-funded through 2028, allowing for the execution of its clinical goals [36] - **Strategic Optionality**: - The decision to pursue both add-on and dual combination strategies provides flexibility in development paths [59][60] - The company emphasizes a data-driven approach to determine the best path forward based on clinical outcomes [60] Conclusion - Ciona Therapeutics is positioned to potentially transform the treatment landscape for cystic fibrosis with its innovative approach targeting CFTR function through NDD1 stabilization. The promising Phase I data and strategic clinical plans highlight the company's commitment to addressing significant unmet needs in the CF patient population.

Summary of Sionna Therapeutics (SION) 2025 Conference Call Company Overview - **Company**: Sionna Therapeutics - **CEO**: Mike Clunan - **Founded**: 2019 as a spin-out from Sanofi, with historical ties to Genzyme [5][6] Industry Focus - **Industry**: Life Sciences, specifically targeting cystic fibrosis (CF) [2][4] - **Market Opportunity**: The current market for CF treatments is valued at $11 billion and is expected to grow [7] Core Points and Arguments 1. **Unmet Need in Cystic Fibrosis**: - Despite advancements by Vertex Pharmaceuticals, a significant unmet need remains in CF treatment [6] - Only one-third of patients on the standard of care, TRIKAFTA, achieve normal CFTR function, indicating a large opportunity for Sionna [6][48] 2. **Targeting NBD1**: - Sionna is focusing on NBD1, a previously considered "undruggable" target, to enhance CFTR correction [7][8] - NBD1 stabilization could potentially deliver clinical benefits comparable to the triple combination therapy of Trikafta [13][23] 3. **Predictive CF HBE Assay**: - The CF HBE assay is a gold standard in vitro assay that is highly predictive of clinical outcomes [8][9] - This assay is used for early screening of compounds and determining exposure targets for clinical trials [9] 4. **Pipeline Development**: - Two NBD1 compounds, 719 and 451, are in Phase 1 trials, with encouraging interim data expected soon [14][15] - Sionna has licensed three complementary mechanisms from AbbVie to enhance their portfolio [10][20] 5. **Combination Strategies**: - The company plans to prioritize two combination assets, Galacaftor and ICL4 corrector (109), to work alongside NBD1 [16][39] - The goal is to create a dual combination that provides meaningful clinical benefits over existing treatments [18][19] 6. **Financial Position**: - Sionna raised $219 million in its IPO, providing financial flexibility and a runway into 2028 [20][46] 7. **Upcoming Milestones**: - Top-line data from Phase 1 studies is expected soon, followed by a Phase 2a proof of concept study to demonstrate the efficacy of NBD1 as an add-on to Trikafta [41][44] - Combination studies with healthy volunteers are also planned to assess tolerability and pharmacokinetics [45] Additional Important Content - **Clinical Endpoint Correlation**: - There is a strong correlation (0.96) between chloride transport and FEV1, with a target of at least a 10 millimole improvement in sweat chloride to demonstrate clinical benefit [53] - **Strategic Flexibility**: - Sionna's unique approach to targeting NBD1 allows for multiple strategies in the market, including layering NBD1 on top of existing therapies [17][18] - **Patient Impact**: - The company aims to shift the treatment paradigm in CF by providing more options and improving patient outcomes [50][49] This summary encapsulates the key points discussed during the conference call, highlighting Sionna Therapeutics' strategic focus, market opportunities, and upcoming milestones in the development of its cystic fibrosis treatments.